Europe has given limited approval to Lilly's Alzheimer's drug, President Trump has announced a trade deal with the EU, Delta ...

Roche’s Alzheimer’s disease therapy has continued to show benefit for patients after 28 weeks in a long-term extension study.

Roche has added another phase 3 trial in its programme for Alzheimer's disease candidate trontinemab and will now test the ...

The therapies, which are just starting to enter clinical trials, will need to prove clear clinical and quality-of-life ...

Swiss drugmaker Roche Holding plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease symptoms, as a part of the company's growing development programmefor the ...

Eli Lilly and Company (NYSE:LLY) is one of the top low volatility healthcare stocks to buy now. On July 10, Morgan Stanley ...

Eli Lilly & Company (NYSE: LLY) ranks among the best non-tech stocks to buy according to billionaires. Eli Lilly & Company ...

These five upcoming data drops could usher in more effective and convenient therapies for Alzheimer’s disease and open up ...

Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, ...

The trial drug Trontinemab is designed to bypass the blood brain barrier, delivering more treatment directly to the brain.

Swiss pharmaceutical giant Roche is set to explore the potential of its experimental drug, Trontinemab, in delaying or ...

What if your doctor could, when you turn 65, order a test that predicts whether you are going to develop Alzheimer’s dementia in your 70s or 80s? And what if – in case the test comes back ...